UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/642,583	08/19/2003	Tadanobu Sato	Q76907	2930
65565 SUGHRUE-26	7590 04/20/200 55550	7	EXAMINER	
2100 PENNSYLVANIA AVE. NW WASHINGTON, DC 20037-3213			WALKE, AMANDA C	
			ART UNIT	PAPER NUMBER
			1752	
			<u>, , , , , , , , , , , , , , , , , , , </u>	
SHORTENED STATUTOR	RY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE	
3 MONTHS		04/20/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

•	LA Brade No	A. alicando)			
	Application No.	Applicant(s)			
Office Action Summan	10/642,583	SATO ET AL.			
Office Action Summary	Examiner	Art Unit			
	Amanda C. Walke	1752			
The MAILING DATE of this communication appeariod for Reply	pears on the cover sheet with th	e correspondence address			
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statut Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION (136(a). In no event, however, may a reply by will apply and will expire SIX (6) MONTHS file, cause the application to become ABANDO	ION. the timely filed from the mailing date of this communication. DNED (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on 16 N	lovember 2006.				
	s action is non-final.				
3) Since this application is in condition for allowed		prosecution as to the merits is			
closed in accordance with the practice under	•				
Disposition of Claims -					
4) Claim(s) <u>1,2,4,6,7 and 9-13</u> is/are pending in	he application.	•			
4a) Of the above claim(s) is/are withdra					
5) Claim(s) is/are allowed.		·			
6) Claim(s) <u>1,2,4,6,7 and 9-13</u> is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and/o	or election requirement.	•			
Application Papers					
9) The specification is objected to by the Examine	er.				
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.					
Applicant may not request that any objection to the					
Replacement drawing sheet(s) including the correct		, i			
11) The oath or declaration is objected to by the E.					
Priority under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 		∂(a)-(d) or (f).			
2. Certified copies of the priority documen	ts have been received in Applic	cation No			
3. Copies of the certified copies of the price		eived in this National Stage			
application from the International Burea * See the attached detailed Office action for a list		eived			
Occ the attached defailed Office action fill a list	or the certified copies flot rece	ivou.			
Attachment(s)					
) Notice of References Cited (PTO-892)	4) 🔲 Interview Summ	ary (PTO-413)			
Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mai	il Date			
I) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	5) Notice of Information	al Patent Application			

C

Application/Control Number: 10/642,583

Art Unit: 1752

DETAILED ACTION

Claim Rejections - 35 USC § 103

- 1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 2. Claims 1, 2, 4, 6, 7, and 9-13 are rejected under 35 U.S.C. 103(a) as being unpatentable over Mydlarz et al (5,783,373 or 5,783,378; column and line citations are for the '373 reference) in view of Edwards et al (5,792,601) in further view of any of Mydlarz et al (6,531,274 or 6,107,018), Budz et al (6,242,172), or Mehta et al (6,265,145).

Mydlarz et al disclose a silver halide photographic material comprising high chloride grains that have been doped with a combination of three dopants which fall within the scope of the present claim limitations. The class (i) dopants fall within the scope of the present class A, the class (ii) dopants fall within the scope of the present classes C and D, and the class (iii) dopants fall within the scope of the present class B (see column 6, line 3 to column 7, line 40, column 12, line 5 to column 14, line 46). For the class (i) dopants, see especially compound i-1, i-4, and i-6, for the class (ii) dopants ii-15; ii-20, and ii-25 (present class C), and ii-1, ii-2 and ii-4 (present class D), and for the class (iii) dopants iii-1 and iii-2. Although the reference does not provide information regarding the electron-release time, it is believed that the dopants of the reference will inherently meet these limitations because they are all listed as being preferred by the present specification. The reference teaches that the dopants of formula ii (present C) may be Ir complexes, but fails to specifically disclose an Ir dopant as instantly claimed.

Application/Control Number: 10/642,583 Page 3

Art Unit: 1752

The Mydlarz et al, Budz et al, and Mehta et al references all teach similar dopants which fall into the scope of the ii dopant of Mydlarz (primary references). Such dopants include pentachlorothiazoleiridium, thus it would have been obvious to one of ordinary skill in the art to prepare the material of either Mydlarz et al reference and choose an Ir dopant of the secondary references. It is also noted that H2O is also a ligand taught to be useful, thus one of ordinary skill in the art would have been motivated to replace the thiazole ligand with H2O.

Edwards et al teaches a high chloride emulsion comprising iodochloride {100} grains, wherein there is a high iodide iodochloride region of the grains. This region is located preferably in the exterior 15 % portion of the grains. Addionally, iridium doped AgBr Lippman emulsions are added to form bromide epitaxial deposits on the surface of the grains (column 6, line 15-column 10, line 21). The presence of both the high iodide iodochloride region of the grains and the doped silver bromide epitaxial deposits result in an increase in sensitivity and contrast.

Given the teachings of the Edwards et al reference, it would have been obvious to one of ordinary skill in the art to prepare the high chloride grains of Mydlarz et al choosing to add both a high iodide iodochloride region in the grains and the doped silver bromide epitaxial deposits of Edwards et al with reasonable expectation of achieving a high chloride emulsion having an increase in sensitivity and contrast.

Response to Arguments

3. Applicant's arguments filed 11/16/2006 have been fully considered but they are not persuasive. Applicant has argued that the dopants of the reference fail to meet the instant claim limitations and states that it would not have been obvious to replace the thiazole with a aquo ligand in the dopant. The examiner has reconsidered the reference, however, the examiner was

Application/Control Number: 10/642,583 Page 4

Art Unit: 1752

referring to the class ii dopants which do not require all six ligands that while it is preferred that a ligand is a thiazole ligand, it is not required, thus it would have been obvious to one of ordinary skill in the art to prepare the dopant with the aqua ligand in the place of the thiazole.

4. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Amanda C. Walke whose telephone number is 571-272-1337. The examiner can normally be reached on M-R 5:30-4.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cynthia Kelly can be reached on 571-272-1526. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

313

Application/Control Number: 10/642,583 Page 5

Art Unit: 1752

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Amanda C Walke Primary Examiner Art Unit 1752

ACW February 5, 2007

AMANDA WALKE

2/5/01